Upper extremity outcome measures for collagen VI-related myopathy and LAMA2-related muscular dystrophy

Bendixen RM, Butrum J, Jain MS, Parks R, Hodsdon B, Nichols C, Hsia M, Nelson L, Keller KC, McGuire M, Elliott JS, Linton MM, Arveson IC, Tounkara F, Vasavada R, Harnett E, Punjabi M, Donkervoort S, Dastgir J, Leach ME, Rutkowski A, Waite M, Collins J, Bönnemann CG, Meilleur KG 
Neuromuscul Disord. 2017. 27(3):278-285.
 The goal of the study was to validate a battery of upper extremity measures in collagen VI-related muscular dystrophy and laminin alpha 2-related dystrophy.
All upper extremity measures were correlated with MFM scores.

PubMed link

Keywords: Collagen VI-related muscular dystrophy; Congenital muscular dystrophy; Laminin alpha 2-related dystrophy; QUEST, Jebsen, Motor Function Measure; Upper extremity measures

Articles dans les revues scientifiques

Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial)

Stam M, Wadman RI, Wijngaarde CA, Bartels B, Asselman FL, Otto LAM, Goedee HS, Habets LE, de Groot JF, Schoenmakers MAGC, Cuppen I, van den Berg LH, van der Pol WL. BMJ Open. 2018. 30;8(7):e019932.  Protocol of the "SPACE" in wich MFM is used as an outcome measure....

read more